Cyriac Abby Philips

Cyriac Abby Philips is an Indian hepatologist and clinician-scientist specializing in clinical and translational hepatology, liver transplant medicine, and drug-induced liver injury. Currently serving as Senior Consultant at Rajagiri Hospital in Kochi, Kerala, he earned his MD in Internal Medicine from Nil Ratan Sircar Medical College and Hospital in Kolkata and has conducted extensive research on liver diseases, authoring over 170 peer-reviewed publications with more than 2,300 citations in major gastroenterology and hepatology journals.

Philips has documented hepatotoxicity associated with herbs and formulations from Indian systems of alternative medicine, including comprehensive reviews linking complementary and alternative medicine to liver damage through empirical analysis of clinical cases and supplement testing. Active on social media as "The Liver Doc," he critiques pseudoscientific claims in wellness products and traditional remedies, emphasizing causal mechanisms of harm such as undisclosed hepatotoxins in marketed supplements. His advocacy earned the 2025 Skeptical Activism Ockham Award from the Committee for Skeptical Inquiry for promoting evidence-based scrutiny of medical misinformation. Despite such pushback, his self-funded studies, like analyses of protein supplements and homeopathic preparations, underscore risks of unregulated alternatives via transparent toxicological evaluations.

Early life and education

Upbringing and family background Cyriac Abby Philips was born on 14 August 1982 in Kottayam, Kerala, India, as the third of four siblings in a family deeply immersed in medicine.

His father, Dr. Philip Augustine, is a pioneering gastroenterologist in Kerala who has practiced for over four decades, performed India's first endoscopic retrograde cholangiopancreatography (ERCP) procedure, and received the Padma Shri award in 2010 for contributions to gastroenterology.

Raised in an environment where medical discussions dominated daily life, Philips was exposed from childhood to topics of diseases, treatments, and hospital operations due to his father's profession, fostering an early familiarity with clinical challenges. . Philips advanced his specialization with a Doctorate of Medicine (DM) in Hepatology from the Institute of Liver and Biliary Sciences (ILBS) in New Delhi, entering the program on 1 August 2013, as part of the 2013–2016 batch focused on hepatology training.

After obtaining his DM, he served as a senior resident at ILBS, gaining further clinical experience in liver and biliary sciences.

In clinical settings, Philips emphasizes evidence-based interventions for alcohol-associated hepatitis, advocating for corticosteroid therapy in select cases of severe disease while highlighting the limitations of unproven treatments such as plasma exchange, which he has critiqued for lacking efficacy in liver failure based on observational outcomes from his patient cohorts. He routinely manages symptoms of advanced liver disease, including ascites, hepatic encephalopathy, and variceal bleeding, prioritizing causal factors like ongoing alcohol use or toxin exposure over symptomatic palliation alone.

Philips' hepatology practice has involved treating numerous cases of drug-induced liver injury, particularly those linked to unregulated herbal and complementary medicines prevalent in India, where he has observed patterns of acute hepatotoxicity leading to transplantation or mortality in otherwise manageable conditions. His approach integrates transplant evaluation for end-stage disease, with a focus on pre- and post-transplant care to mitigate drug interactions and recidivism risks in recipients. This work underscores a commitment to causal realism in therapy, rejecting interventions without empirical support from controlled data.

Philips co-authored the updated consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) on ACLF, incorporating empirical data on diagnostic criteria, prognostic models, and therapeutic interventions from over 10,000 patients across multiple studies, highlighting regional variations in etiology such as viral hepatitis and alcohol. Another study examined endoscopy timing in 500+ cirrhotics with variceal hemorrhage, finding delays beyond 12 hours increased rebleeding risk by 45% (p<0.01).

In therapeutic research, Philips evaluated fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis, reporting pilot data on 20 patients with improved survival (60% at 90 days) versus historical controls, linked to restored gut-liver axis homeostasis.

Philips has published over 250 peer-reviewed articles, with contributions to international registries on hepatocellular carcinoma surveillance in Kerala, India, involving 1,500+ cases and identifying gaps in early detection (stage I diagnosis in only 22%). These accolades recognize his role in advancing prognostic tools, such as machine learning models for in-hospital mortality in cirrhotic bleeding (AUC 0.85).

Scientific critique of alternative medicine

Evidence-based analysis of herbal hepatotoxicity Cyriac Abby Philips has extensively documented cases of herbal-induced liver injury (HILI) attributable to herbs in Indian AYUSH systems, particularly Ayurveda, through case series, histopathological analyses, and literature reviews spanning 2019 to 2024. Philips argues that inherent phytochemical toxicity, rather than solely contamination or adulteration, drives many instances, as chemical analyses of implicated products frequently reveal unadulterated natural compounds. His analyses often incorporate histopathological findings, chemical assays, and causality assessments like the Roussel Uclaf Causality Assessment Method, revealing high mortality risks in patients with preexisting liver conditions. In 2023, he co-reported a series of severe DILI cases from homeopathic remedies in Hepatology Communications, highlighting patterns of acute hepatitis and the need for regulatory scrutiny of such CAM modalities.

His 2024 contribution to Hepatology Communications synthesized global CAM-DILI trends, noting presentations from asymptomatic enzyme elevations to vanishing bile duct syndrome and autoimmune-like hepatitis; preexisting liver disease was identified as a predictor of progression to failure and reduced transplant-free survival, alongside critiques of "liver-beneficial" herb myths and advocacy for enhanced patient education and regulation.

Public advocacy and online presence

Social media engagement as "The Liver Doc" Cyriac Abby Philips maintains an active presence on social media platforms under the pseudonym "The Liver Doc," leveraging them to disseminate evidence-based information on hepatology and counter health misinformation. His primary outlet is X (formerly Twitter), where the account @theliverdr has accrued 314,056 followers and features over 59,000 posts as of October 2025, focusing on critiques of unproven remedies and their links to drug-induced liver injury. Philips employs a direct, data-driven style, often citing clinical studies and patient case reports to challenge claims from alternative medicine proponents, emphasizing empirical risks over anecdotal endorsements.

On Instagram (@theliverdr), Philips shares visual aids, infographics, and reels elucidating liver pathology and the hepatotoxicity of herbal supplements, garnering engagement through educational threads on topics like the dangers of unchecked polyherbal use. His content routinely addresses public queries on liver health, such as warnings against self-medication with substances like Giloy, which he has labeled highly liver-toxic based on observed clinical patterns. This approach fosters interaction with a broad audience, including patients and skeptics, while promoting rigorous scientific scrutiny over traditional or influencer-driven narratives.

Philips' engagement extends to real-time responses to viral misinformation, such as debunking celebrity-endorsed practices involving nebulized hydrogen peroxide or unverified supplements, positioning his accounts as counterpoints to pseudoscientific trends. Despite platform restrictions, including a 2023 temporary suspension of his X account following defamation claims by a supplement firm, he has restored and sustained visibility, underscoring his commitment to accessible public advocacy. His strategy prioritizes verifiable medical evidence, drawing from peer-reviewed hepatotoxicity data to inform followers on causal links between alternative therapies and adverse outcomes.

Debunking pseudoscientific claims Cyriac Abby Philips, under his online persona "The Liver Doc," has actively debunked pseudoscientific health claims on social media, emphasizing the lack of empirical evidence and potential risks to patients. His critiques target unsubstantiated assertions in alternative medicine, wellness trends, and celebrity-endorsed remedies, often highlighting how they contradict established hepatological data. For instance, in July 2024, he refuted actress Nayanthara's promotion of hibiscus tea as a cure for polycystic ovary syndrome and other conditions, labeling the claims "false and inaccurate" due to insufficient clinical trials supporting efficacy and risks of herb-drug interactions.

Philips has similarly challenged "detox" fads, arguing that purported liver-cleansing products and practices lack mechanistic plausibility and can exacerbate hepatic stress, as the human liver naturally detoxifies without external aids. In a June 2023 analysis, he dissected a viral video promoting Himalayan salt ("sendha namak") as superior for health, pointing out that mineral content variations do not confer benefits over regular salt and that such claims ignore sodium's uniform physiological impact. He extended this to religious-framed assertions, such as tulsi leaves being rich in protective compounds, noting in April 2022 that no peer-reviewed studies validate antiviral or detoxifying effects amid high mercury contamination risks in some samples.

His debunkings extend to high-profile influencers, including a 2023 critique of podcaster Andrew Huberman for promoting unverified neuroscience-based health hacks lacking plausibility and validity. In April 2025, Philips accused anti-aging entrepreneur Bryan Johnson of fraud for Blueprint protocol claims, citing absence of long-term randomized controlled trials and overreliance on anecdotal biomarkers. Philips frames these efforts as opposition to "anything unscientific, pseudoscientific, or rooted in faith," prioritizing causal evidence over anecdotal or traditional appeals, which he argues misleads vulnerable patients toward hepatotoxic alternatives.

Through threads and videos, Philips advocates for evidence-based scrutiny, warning that social media amplifies misinformation—such as unproven home remedies for symptom relief—driving misuse over targeted etiology-based treatments. His approach underscores systemic issues in India's wellness sector, where cultural reverence for traditional systems like Ayurveda often shields pseudoscientific marketing from rigorous testing, despite documented adverse events.

Controversies and legal challenges

Lawsuits from supplement industry In September 2023, Himalaya Wellness Corporation, an Indian herbal supplement manufacturer, filed a defamation lawsuit against Cyriac Abby Philips in a Bengaluru civil court, accusing him of making false and unjustified statements on social media about their product Liv.52, which allegedly caused business losses. The suit stemmed from Philips' posts since 2019 questioning Liv.52's efficacy and linking it to cases of liver injury, claims he supported with references to peer-reviewed studies on herbal hepatotoxicity.

The court granted an ex parte interim injunction on 28 September 2023, ordering the global suspension of Philips' X (formerly Twitter) account, @theliverdoc, and prohibiting further public discussion of Himalaya products pending resolution. Although not a direct suit against Philips, the action highlighted industry pressure on his critiques of supplement safety. Philips has consistently framed such challenges as attempts to suppress evidence-based warnings on unregulated supplements, citing his clinical observations of drug-induced liver injury patterns. In November 2023, Philips lodged a formal complaint with Kerala Police against a prominent right-wing social media influencer for inciting abuse, stemming from his debunking of claims by an Ayurveda advocacy group.

The cultural dimension is evident in responses portraying Ayurveda not merely as medicine but as an emblem of civilizational pride, leading to doxing, boycott calls, and persistent online campaigns against Philips since at least 2017. While some defenses of traditional systems invoke empirical traditions within Ayurveda, critics like Philips argue that such reactions prioritize identity over verifiable safety data, exacerbating risks from unstandardized products. No formal investigations into the organized abuse have been publicly detailed beyond Philips's complaint, highlighting challenges in addressing digital harassment tied to cultural-political narratives.

The selection criteria emphasized Philips' resilience against harassment, legal threats, and industry litigation from proponents of alternative therapies, including cases where his research papers on supplement-induced toxicities—such as a 2019 study linking a patient's death to a toxic herbal product—faced retraction and subsequent reinstatement following external pressures. His critiques have sparked debates on the tension between cultural traditionalism and scientific validation, especially in contexts where government initiatives promote AYUSH without rigorous toxicity surveillance, leading to increased public and media scrutiny of industry practices. Endorsements from physician networks advocating healthcare reforms affirm his contributions to combating infodemics, positioning him as a proponent of clinician-led public education against pseudoscientific encroachments on evidence-based policy.

Personal life

Family and residence Cyriac Abby Philips resides in Kochi, Kerala, India, where he serves as a senior consultant hepatologist at facilities including Rajagiri Hospital and the Ernakulam Medical Center. His professional base in Kochi aligns with his clinical and research work in hepatology, conducted through affiliations such as the Cochin Gastroenterology Group and Monarch Liver Lab. His family life intersects with his veterinary interests, as he has shared experiences with pet dogs that have positively influenced his household.

Interests outside medicine Philips maintains an active interest in canine companionship, owning multiple dogs including a pug named Penny, a boxer named Bella, and a Dalmatian puppy named Juniper, with a deceased Dalmatian named Bingie also part of the family history. He has highlighted the positive impacts of these pets on family dynamics, noting their role in fostering humility, empathy, and social skills in children, while citing scientific evidence for benefits such as reduced risks of obesity and asthma in pet-owning households.